Varicella zoster virus (VZV) is the most common virological cause of disease in the elderly. Primary infection causes varicella, after which virus becomes latent in ganglia along the entire neuraxis. By 2050, >83 million Americans will be >65 years old with 95% harboring latent VZV. As the immune system ages, VZV will reactivate in >50% of Americans by 85 years of age to produce zoster, which can be complicated by postherpetic neuralgia. During reactivation, VZV can also cause giant cell arteritis (GCA), which is the most common systemic vasculitis in the elderly characterized by severe headache and scalp tenderness, as well as a history of jaw claudication, polymyalgia rheumatica, fever, night sweats, weight loss, fatigue, and elevated serum inflammatory markers. GCA is a medical emergency that leads to vision loss; thus, patients are treated with corticosteroids, with 50% relapsing or progressing to stroke and vision loss despite therapy. By 2050, in the US, the estimated cost from visual impairment due GCA will exceed $76 billion. TA biopsy from GCA patients typically reveals transmural inflammation, medial damage and multinucleated giant/epithelioid cells (GCA-positive TAs) but may be pathologically negative (GCA-negative). Recently, we showed that 70% GCA- positive TAs and 58% GCA-negative TAs contain VZV antigen, as well as VZV DNA and herpesvirus particles in a subset, whereas only 18% normal TAs contained VZV antigen. The pathologic finding in GCA-positive and -negative TAs is persistent inflammation leading to vascular wall damage that we suspect is triggered by VZV infection. Taken together, we hypothesize that VZV elicits persistent vascular inflammation in TAs of patients with giant cell arteritis through production of a proinflammatory environment and recruitment of VZV-specific T cells. We will test this hypothesis by analyzing the proinflammatory environment and identifying biomarkers and pathways supportive of VZV infection in FFPE GCA-positive, GCA-negative and normal TAs with and without VZV antigen using TempO-Seq and pathway analysis programs (Aim 1) and determining if VZV- specific CD4 T cells are locally enriched in fresh TA biopsies of GCA (Aim 2). Elucidating the role of VZV in GCA will provide information on promising pathways to target in order to mitigate GCA and on biomarkers for disease susceptibility that may be extended to other VZV vasculopathies, ultimately guiding clinical decision- making and therapies, as well as improving quality of life and reducing health care costs. Successful completion of these Aims is supported by multidisciplinary collaborations by experts in neurology, ophthalmology immunology bioinformatics/statistics, the availability of archived FFPE TAs and fresh biopsy tissue and excellent environment of neurovirologists at the University of Colorado Department of Neurology. Elucidating the role of VZV in GCA will provide information on promising pathways to target in order to mitigate GCA and on biomarkers for disease susceptibility that may be extended to other VZV vasculopathies, ultimately guiding clinical decision-making and therapies, as well as improving quality of life and reducing health care costs.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG032958-13
Application #
10097964
Study Section
Special Emphasis Panel (ZAG1)
Project Start
2009-03-01
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
13
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Como, Christina N; Pearce, Catherine M; Cohrs, Randall J et al. (2018) Interleukin-6 and type 1 interferons inhibit varicella zoster virus replication in human neurons. Virology 522:13-18
Mahalingam, Ravi; Kaufer, Benedikt B; Ouwendijk, Werner J D et al. (2018) Attenuation of Simian Varicella Virus Infection by Enhanced Green Fluorescent Protein in Rhesus Macaques. J Virol 92:
Cohrs, Randall J; Badani, Hussain; Baird, Nicholas L et al. (2017) Induction of varicella zoster virus DNA replication in dissociated human trigeminal ganglia. J Neurovirol 23:152-157
Cohrs, Randall J; Lee, Katherine S; Beach, Addilynn et al. (2017) Targeted Genome Sequencing Reveals Varicella-Zoster Virus Open Reading Frame 12 Deletion. J Virol 91:
Nagel, Maria A; Jones, Dallas; Wyborny, Ann (2017) Varicella zoster virus vasculopathy: The expanding clinical spectrum and pathogenesis. J Neuroimmunol 308:112-117
Ouwendijk, Werner J D; van Veen, Suzanne; Mahalingam, Ravi et al. (2017) Simian varicella virus inhibits the interferon gamma signalling pathway. J Gen Virol :
Jones, Dallas; Alvarez, Enrique; Selva, Sean et al. (2016) Proinflammatory cytokines and matrix metalloproteinases in CSF of patients with VZV vasculopathy. Neurol Neuroimmunol Neuroinflamm 3:e246
Gilden, Don; White, Teresa; Boyer, Philip J et al. (2016) Varicella Zoster Virus Infection in Granulomatous Arteritis of the Aorta. J Infect Dis 213:1866-71
Keller, Amy C; Badani, Hussain; McClatchey, P Mason et al. (2016) Varicella zoster virus infection of human fetal lung cells alters mitochondrial morphology. J Neurovirol 22:674-682
Gilden, Don; White, Teresa; Khmeleva, Nelly et al. (2016) Blinded search for varicella zoster virus in giant cell arteritis (GCA)-positive and GCA-negative temporal arteries. J Neurol Sci 364:141-3

Showing the most recent 10 out of 124 publications